



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **David Weisman, M.D.**

Committees: **Joint meeting of the Psychopharmacologic Drugs Advisory Committee and Peripheral and Central Nervous System Drugs Advisory Committee**

Meeting Date: **April 14, 2023**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

The committees will discuss supplemental new drug application (sNDA) 205422 s009, efficacy supplement for Rexulti (brexpiprazole) tablets, submitted by Otsuka Pharmaceutical Company, Ltd., and Lundbeck, Inc., for the proposed treatment of agitation associated with Alzheimer’s dementia.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Contract/grant	Employer’s research funded by Johns Hopkins Bloomberg School of Public Health Center for Clinical Trials and National Institute on Aging, unrelated entities	\$5,000 - \$15,000 per year to Abington Neurological Associates  \$0 - \$5,000 per year in salary support to Dr. Weisman.

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_\_/03/22/23\_\_\_\_\_  
Date